Samumed is a biotech startup based in San Diego, California. Recently, the firm presented promising data from phase 2 trials of a potential treatment for androgenetic alopecia (AGA) known as SM04554.
The study involved 49 subjects in a multi-center, randomized, double-blind, vehicle-controlled trial. The participants applied the treatment once daily for 90 days. Data was collected via a 4mm scalp biopsy at baseline (Day - 26), Day 91 and Day 135 to assess the safety and efficacy of two different concentrations (0.15% and 0.25%) of SM04554 versus vehicle in male subjects with AGA, between the ages of 18 and 65 exhibiting Norwood Scale hair loss classifications of 4, 5, 5A, 5V, or 6.
According to Yusuf Yazici, M.D., Chief Medical Officer of Samumed,
“Follicle count data from observations at the tissue level in this biopsy study, together with non-vellus hair count increases we observed in past studies, are very exciting for the future prospects of SM04554 as a
potential hair regeneration drug” .
For more information on this exciting hair restoration development, see the official press release.
© 2001 - 2020 Media Visions, Inc